A Phase 2b clinical trial of MH002 in patients with mild-to-moderate ulcerative colitis.
Latest Information Update: 28 Oct 2025
At a glance
- Drugs MH 002 (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
Most Recent Events
- 28 Oct 2025 New trial record
- 04 Sep 2025 According to a MRM Health media release, Funding to support Phase 2b trial with MRM Healths lead program MH002 in ulcerative colitis and advance two additional programs to IND approval.Proceeds will enable MRM Health to complete a Phase 2b clinical trial for its lead program MH002 in patients suffering from mild-to-moderate ulcerative colitis.